CN Mobile Logo

Search form


Mark L. Fuerst

Mark L. Fuerst

Mark L. Fuerst is a freelance health and medical writer for ConsultantLive, Rheumatology Network, Psychiatric Times, and other UBM publications. He writes about rheumatology, psychiatry, neurology, endocrinology, oncology, and men’s health.

Posts by Author

An anti–PD-1 monoclonal antibody is safe and effective for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma.

Perioperative chemotherapy with a docetaxel-based triplet should be considered the new standard of care for resectable gastric or GEJ adenocarcinoma.

The second-generation ALK-inhibitor alectinib should be the new standard of care for first-line treatment of ALK-positive non–small-cell lung cancer, according to a new study.

Clinicians need to track not only current alcohol consumption among their HIV-infected patients—but also past use.

Immunotherapy may represent an effective new treatment approach for relapsed mesothelioma patients, according to a new study.

Breast cancer survivors, including those with estrogen receptor–positive tumors, can safely become pregnant, according to a new study.

Women infected with the human immunodeficiency virus (HIV) are more likely to have human papillomavirus (HPV) infection that progresses to pre-cancerous cervical lesions.

Both oncologists and cancer patients recognize the benefits of physical activity during treatment, but oncologists may feel ill-equipped to give recommendations on exercise, according to a new study.

Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non–small-cell lung cancer.

©Sean K/Shutterstock.com

Antiretroviral therapy has dramatically reduced AIDS-associated morbidity and mortality -- but only in those who know they are HIV positive and if they maintain sustained engagement with care.


By clicking Accept, you agree to become a member of the UBM Medica Community.